OTHER RIBO STUDIES

_____________ Evaluated Efficacy and Safety of 400 mg Ribociclib + NSAI vs 600 mg Ribociclib + NSAI in Pre-/Postmenopausal Women With HR+, HER2– ABC. Identify this study.

• AMALEE

• COMPLEEMENT

• MAINTAIN

• RIGHT CHOICE

• HARMONIA

Noninferiority of ORR with 400 mg vs 600 mg ribociclib. Identify this study.

• AMALEE

• COMPLEEMENT

• MAINTAIN

• RIGHT CHOICE

• HARMONIA

PFS Was Similar Between 400 mg and 600 mg Groups, but Data Were Not Mature. Identify this study.

• AMALEE

• COMPLEEMENT

• MAINTAIN

• RIGHT CHOICE

• HARMONIA

A PFS Benefit of ≈1 Year Was Observed in Patients Receiving Ribociclib + AI. Identify this study.

• AMALEE

• COMPLEEMENT

• MAINTAIN

• RIGHT CHOICE

• HARMONIA

__________, the First Prospective, Head-to-Head Phase III Trial to Evaluate Ribociclib vs Palbociclib in Patients With HR+, HER2–, HER2-E ABC. Identify this study.

• AMALEE

• COMPLEEMENT

• MAINTAIN

• RIGHT CHOICE

• HARMONIA

Median TTF Was Improved With Ribociclib + AI, but ORR Was Similar Between Treatment Arms. Identify this study.

• AMALEE

• COMPLEEMENT

• MAINTAIN

• RIGHT CHOICE

• HARMONIA

The objective of this study is to assess the Safety and Efficacy of Ribociclib + Letrozole in Men and Women Who Have Not Received Prior ET for HR+, HER2– ABC. Identify this study.

• AMALEE

• COMPLEEMENT

• MAINTAIN

• RIGHT CHOICE

• HARMONIA

An open-label, single-arm, multicenter, phase 3b study of ribociclib + letrozole in a larger and broader patient population than MONALEESA-2. Identify this study.

• AMALEE

• COMPLEEMENT

• MAINTAIN

• RIGHT CHOICE

• HARMONIA

Patients included were women (any menopausal status) and men with HR+, HER2– ABC. Identify this study.

• AMALEE

• COMPLEEMENT

• MAINTAIN

• RIGHT CHOICE

• HARMONIA

The Overall Safety Profile of Ribociclib Was Similar to That Observed in the MONALEESA-2 and MONALEESA-7 Trials. Identify this study.

• AMALEE

• COMPLEEMENT

• MAINTAIN

• RIGHT CHOICE

• HARMONIA